What changed in Biodexa Pharmaceuticals Plc's 2023 10-K compared to 2022?

Across the narrative sections we track, Biodexa Pharmaceuticals Plc (BDRX) added 0 paragraphs, removed 0, and edited 0 between the 2022 and 2023 10-K filings. The biggest movers are .

Where does this BDRX 10-K diff come from?

The source filings are Biodexa Pharmaceuticals Plc's official 2022 and 2023 Form 6-K annual reports from SEC EDGAR. 10q10k.net parses each filing, aligns paragraphs by section (Item 1, 1A, 1C, 2, 3, 7, 7A), and highlights every added, removed and edited sentence side-by-side.

Biodexa Pharmaceuticals PlcBDRX決算レポート

Nasdaq

Biodexa Pharmaceuticals Plc is a clinical-stage biopharmaceutical company focused on developing innovative therapies for central nervous system disorders, including epilepsy and rare neurodegenerative conditions. It operates primarily across European and North American markets, advancing multiple pipeline candidates through clinical trials to address unmet patient needs.

What changed in Biodexa Pharmaceuticals Plc's 6-K — 2022 vs 2023

No meaningful paragraph-level changes detected in the compared sections. Either the two filings are nearly identical or the sections did not parse.